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Background: We aimed to examine the expression of miR-1307 in chemosensitive and chemoresistant epithelial
ovarian cancer tissues and cell lines and to analyze the clinicopathological significance of miR-1307 in ovarian cancer.
Methods: MicroRNA microarray was used to screen differentially expressed microRNAs between the chemosensitive
and chemoresistant epithelial ovarian cancer tissues. RT-PCR was used to validate the candidate microRNA. The
potential target genes and their enriched biological pathways of microRNA were also analyzed. Dual Luciferase
Reporter Gene Assay was conducted to validate the regulation of miRNA-1307 on the 3’-UTR of DAPK3.
Results: miRNA-1307 was up-regulated in the chemoresistant epithelial ovarian cancer tissues compared to the
chemosensitive counterparts. The up-regulation of miRNA-1307 was not associated with menopause, tumor
differentiation state, clinical stage, and lymph node metastasis of ovarian cancer. Gene ontology analysis of
miR-1307 candidate target genes indicated that miR-1307 candidate target genes were enriched in the processes
of cell proliferation and differentiation, nucleotide synthesis and metabolism, and lymphocytes activation.
Conclusion: Our results suggest that miRNA-1307 may play a role in the development of chemoresistance in
ovarian cancer.
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Epithelial ovarian carcinoma has the highest mortality
rate in gynecological cancers. In fact, 52% of death
caused by gynecological cancer are contributed by the
epithelial ovarian carcinoma [1]. The current standard
treatment strategy for epithelial ovarian carcinoma is
cytoreductive surgery followed by platinum-based
chemotherapy. Despite the advancements in the diagno-
sis and treatment of ovarian cancer, the 5-year survival
rate for advanced ovarian cancer is poorly 30% [2].The
main reasons for the high mortality of ovarian cancer
include: early stage of ovarian cancer are usually asymp-
tomatic; lack of diagnostic methods for early stage of
ovarian cancer; and the development of chemoresistance
during chemotherapy [3]. Past studies have shown that
chemoresistance occurred in 1/3 of patients received
platinum-based chemotherapy. In addition, nearly all
recurrent ovarian tumors are resistant to platinum-* Correspondence: wm21st@hotmail.com
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unless otherwise stated.containing chemotherapy drugs [4]. Because the develop-
ment of chemoresistance is associated with a greatly
reduced survival rate for ovarian cancer patients, there is
an urgency to discover new therapeutic approaches to
reduce the occurrence of chemoresistance.
MicroRNA (miRNA) is a class of small non-coding
RNA molecule that was first discovered in 1993 [5].
miRNA plays an important regulatory role for gene ex-
pression by directly binding to the 3’ UTR of target
mRNAs [6]. Numerous studies have demonstrated that
miRNA is a critical factor in many biological processes,
such as cell differentiation, cell proliferation, apoptosis,
and energy metabolism [7]. Interestingly, miRNA has
been shown to have dual roles in the development of
cancer, either promotes carcinogenesis by inhibiting
tumor suppressors or acts as tumor suppressors to
down-regulate oncogenes [8]. Recently, there are increas-
ing interests in studying the association between miRNA
and ovarian cancer. Several studies have reported that
miRNA is involved in the development of chemoresistance
in ovarian cancer by inhibiting pro-apoptotic signalhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Zhou et al. Journal of Ovarian Research  (2015) 8:23 Page 2 of 7pathway [3]. The loss of let-7 has been considered contrib-
ute to the chemoresistance in ovarian cancer cells [9]. Up-
regulation of miR-300 can inhibit cellular apoptosis via
TGF-β signaling and thus promotes chemoresistance in
ovarian cancer cells 11. Therefore, the dysregulation of
miRNA may be a critical factor that determines the sensi-
tivity of ovarian cancer cells to chemotherapy.
In this study, we conducted a miRNA screening using
the miRNA microarray to search for differentially
expressed miRNAs between the chemosensitive and che-
moresistant ovarian cancer tissues. We then validated
the results of miRNA microarray analysis.Materials and methods
Ovarian tumor samples
8 cases of sporadic ovarian serous cystadenocarcinoma
(4 chemoresistant and 4 chemosensitive) were used for
the microRNA microarray analysis. All samples were
obtained from surgical operations in the Shengjing hos-
pital of the China Medical University. All cases were
pathologically confirmed and no treatments were given
before surgery. The age range for the chemoresistant
group was from 42 to 79 years old with a median of
50.5. The age range for the chemosensitive group was
from 33 to 71 years old with a median of 57.0. All pa-
tients received cytoreductive surgery and 6–8 cycles of
TP chemotherapy regimen (paclitaxel + cisplatin) after
surgery. Chest X-ray was obtained before surgery.
Tumor response was evaluated in patient follow-up.
Physical exam, ultrasound, and CA125 test were per-
formed during each patient follow-up. CT, MRI and
PET scan were also performed when it is necessary.
NCCN guideline for ovarian cancer was used to deter-
mine the chemosensitivity and resistance. A tumor is
chemosensitive if there is no tumor recurrence within
6 months of the initial chemotherapy and chemoresis-
tant if there is. The study was approved by the Ethic
Committee of Shengjing Hospital of China Medical
University, approval number was 2014PS14K. All pa-
tients provided informed consents.
40 cases of ovarian serous cystadenocarcinoma (20
chemoresistant and 20 chemosensitive) were used in
the RT-PCR validation for candidate miRNA obtained
from the miRNA microarray screening. All samples
were obtained from surgically dissected tumors in the
Shengjing hospital of the China Medical University be-
tween January 2009 and January 2012. Patients received
the TP chemotherapy regimen (paclitaxel + cisplatin)
after surgery. Tumor response was evaluated in patient
follow-up for 6 months. The criteria for chemosensitivity
and resistance is the same as above. Clinical staging were
based on the International Federation of Gynecology and
Obstetrics (FIGO) stage.Cell culture
Human ovarian cancer cell line SKOV3 and SKOV3-
TR30 (resistant to paclitaxel) was obtained from the
Women’s hospital of the Zhejiang University School of
Medicine. SKOV3 cells were maintained in RPMI-1640
medium (10% FBS, 100 μg/ml penicillin and 100 μg/ml
streptomycin). SKOV3-TR30 cells were maintained in
the same medium as SKOV3 with 30 nmol/L paclitaxel.
All cells were incubated at 37°C with 5% CO2.
MicroRNA microarray
Affymetrix microRNA microarray was used in this study
(GeneChip® miRNA 4.0 Array, Affymetrix). Experiment
was performed according to the instruction of the
manufacturer. The Cluster 3.0 software was used for the
analysis of microRNA expression. The criteria for differ-
entially expressed miRNA is |Score (d)| ≥2, and fold
change ≥2 or ≤0.5.
RT-PCR
Total RNA were extracted from 50-100 mg of frozen
tumor tissues using Trizol (Invitrogen). Reverse transcrip-
tion was performed according to manufacturer’s instruc-
tion (Primescript TM RT reagent Kit, TaKaRa). The
TagMan microRNA kit (TaKaRa) was used for the real
time PCR to assess the expression level of the candidate
microRNA. PCR cycle conditions are: 95°C for 5 minutes,
followed by 40 cycles of 95°C 10s, 60°C 20s, 72°C 20s, and
78°C 20s. The primers for miR-1307 are: forward primer
5’-AACTCGGCGTGGC -3’; reverse primer 5’-GAGCAG
GCTGGAGAA-3’. U6 was used as internal control in RT-
PCR: forward primer 5’-GCTTCGGCAGCACATATACT
AAAAT-3’; reverse primer 5’-CGCTTCACGAATTTGCG
TGTCAT-3’; Experiment was performed independently
for three times.
Analysis of miRNA target genes and gene ontology
analysis
TargetScan, miRanda and Diana microT-CDS were used
to analyze the potential target genes for miR-1307. GOstat
was used for gene enrichment analysis. The DAVID
database was used for signal transduction enrichment
analysis.
Reporter assay for DAPK3
pMIR-REPORT-DAPK3 and pMIR-REPORT-DAPK3-mut
reporters were used to validate the regulatory effect of
miRNA-1307 on DAPK3. The 336 bps of DAPK3
(NM_001348) contains a potential miRNA-1307 binding
site in the 3’-UTR were cloned into the pMIR-REPORT
vector by the SpeI and HindIII restriction enzyme cutting
sites. The site-directed mutagenesis kit (Beyotime, China)
was used to induce five nucleotides mutations in the
pMIR-REPORT-DAPK3-mut. The mutation on DAPK3
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CATTCTG). For luciferase reporter assay, HEK293 cells
were seeded in 24-well plates for 24 hours to reach
confluency of 70-80% before transfecting reporter con-
structs. pMIR-REPORT-DAPK3 and pMIR-REPORT-
DAPK3-mut were then transfected into HEK293 cells
with Renilla luciferase normalization plasmid (pELTK).
Luciferase reporter activity was measured 24 hours
after transfection and normalized by Renilla reporter
signals (Promega).
Statistical analysis
The Fisher Exact Test was used to calculate p value.
ANOVA was used to compare the mean values of the
results of luciferase assay among the three groups. The
Bonferroni test was used to compare the mean values
of the luciferase assay results between two groups. A p
value <0.05 indicated statistically significant. SPSS17.0
was used for statistical analysis.Figure 1 MicroRNA microarray screening for differentially expressed
tumors, while T5, T7, T8 and 1015044 were chemoresistant ovarian cancer
cancer cell lines respectively. The miRNA expression profile of miR-210, miRResults
Upregulation of miR-1307 in chemoresistant ovarian
tumors
To search for differentially expressed miRNA that may
play a role in the development of chemoresistance in
ovarian cancer, we compared the miRNA expression
profile between 4 chemosensitive and 4 chemoresistant
ovarian tumor samples. As a result, we discovered that
miR-1307 was upregulated in chemoresistant ovarian
tumors when compared to the chemosensitive ovarian
tumors (Figure 1). To validate this result, we performed
quantitative RT-PCR for miR-1307 in 20 chemosensitive
and 20 chemoresistant ovarian carcinoma samples. We
found that the expression level of miR-1307 was 4.41
folds higher in chemoresistant ovarian tumors com-
pared to the chemosensitive ovarian tumors (p = 0.001,
Figure 2). Consistently, the expression level of miR-
1307 was 2.81 folds higher in the SKOV3-TR30 cells,
which is a chemoresistant clone of the ovarian cancermiRNAs. C1, C3, C4 and 20101585 were chemosensitive ovarian
tissues. SK1 and SKT2 were chemosensitive and chemoresistant ovarian
-1307 and miR-134 were also shown.
Table 1 Clinicopathological relevance of miR-1307 upreg-
ulation in ovarian carcinoma
Parameters Case no. miR-1307 level p value
Age 0.8011
Postmenopause 25 2.137 ± 1.1457
Before menopause 15 2.540 ± 1.1282
Differentiation status 0.6080
High or medium 18 2.917 ± 1.0120
Low 22 2.138 ± 1.297
Clinical stage 0.4985
Stage I 3 1.404 ± 0.8790
Stage II 8 3.880 ± 1.4341
Stage III 29 3.945 ± 1.3631
Lymph node metastasis 0.3257
Yes 15 2.497 ± 1.3521
No 25 4.347 ± 2.0142
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(p = 0.001, Figure 2).
Cliniopathological relevance of miR-1307 in ovarian
cancer
To examine the clinicopathological relevance of miR-1307
upregulation in ovarian cancer, we analyzed the level of
miR-1307 with a number of clinical and pathological
parameters. We found that there was no statistically
significant association between the expression level of
miR-1307 and menopause, tumor differentiation status,
clinical staging and lymph node involvement (Table 1).
To determine the cutoff value of miR-1307 as a pre-
dicting factor for chemoresistance in ovarian cancer, we
performed the ROC analysis. We thus found the cut-of
level was 2.1579, which suggested that chemoresistance
of paclitaxel may be developed if 2-△△Ct of miR-1307 is
more than 2.1579 in RT-PCR and change of therapeutic
regimen should be considered.
Analysis of miR-1307 candidate target genes
To gain an insight to the regulatory network of miR-
1307, we performed bioinformatics analysis to identify
potential miR-1307 target genes. As a result, an analysis
of Targetscan、miRanda、Pita returned 124 common can-
didate genes for miR-1307. Biological pathway analysis
showed that miR-1307 candidate genes were enriched in
organogenesis, gene transcription, cell proliferation and
differentiation, neurogenesis, T cell activation, vitamin
synthesis and metabolism pathways (Additional file 1).
To validate the targets of miRNA-1307, we constructed
the reporter assay system for DAPK3, which is a potentialFigure 2 Upregulation of miR-1307 in chemoresistant ovarian cancer
chemosensitive ovarian cancer tissues and 20 chemoresistant ovarian cancer
SKOV-3 and chemoresistant SKOV-3TR cells were also shown. *indicates p = 0.regulatory target of miRNA1307 that has been consistently
identified in our bioinformatics analysis. We found that
the reporter activity level of DAPK3 was significantly re-
duced compared to the control (p = 0.01, Figure 3). This
result was confirmed when the suppressive effect of
miRNA-1307 was abolished on the mutated DAPK3
reporter.
Discussion
miRNA has been long linked to the development of che-
moresistance [10]. With the advancement of miRNA
microarray technology, we can now evaluate the miRNAtissues and cell line. RT-PCR analysis of miR-1307 expression in 20
tissues were compared. The relative expression level of chemosensitive
001.
Figure 3 Validation of DAPK3 as a target of miRNA-1307.
Luciferase reporter assay using pMIR-REPORT-DAPK3, pMIR-
REPORT-DAPK3-mut and control were shown.
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this study, we used the miRNA microarray to search for
differentially expressed miRNAs that are specific to
chemoresistance in epithelial ovarian carcinoma. As a
result, we found that miR-1307 was upregulated in che-
moresistant ovarian cancer when compared to the chemo-
sensitive ovarian cancer. This result was confirmed by
RT-PCR in 20 chemoresistant and 20 chemosensitive
ovarian cancer tissues, indicating that miR-1307 was asso-
ciated with chemoresistance in ovarian cancer.
microRNA is an important post-transcriptional regula-
tor of gene expression. miRNA has been estimated to
regulate more than 30% of mRNAs in human cells [11].
Studies have demonstrated that multiple miRNAs can
regulate one gene while one miRNA can regulate mul-
tiple target genes, weaving a complex regulatory network
for the delicate regulation of gene expression in
eukaryotic cells [12]. In the past decade, numerous stud-
ies have shown that dysregulation of miRNA may con-
tribute to the development of cancer. For examples,
miR-15a, miR-16-1, and miR-126 act as tumor suppres-
sor to downregulate oncogenes [13,14]. In contrast,
miR-135, MiR-522, miR-15b, and miR-490-3p function
to promote cancer development and progression
[15-18]. In addition, miRNA has been shown to regulate
noncoding regions of genome that are important in the
tumorigenesis [19].
Recently, many research have shown that the resist-
ance of ovarian cancer to chemotherapeutic drugs is reg-
ulated by miRNA. There is a significant difference in
miRNA expression profile between the chemosensitive
and chemoresistant ovarian cancer cells. The study by
Yu et al. showed that the downregulation of miR-29 in-
creased resistance to cisplatin in ovarian cancer cells
[20]. MiR-106a and miR-591 have important roles inconferring paclitaxel resistance to ovarian cancer cells,
and modulating miRNAs to resensitize paclitaxel-resistant
cancer cells by regulating BCL10, caspase-7, and ZEB1
[21]. In the study by Cittelly et al., the chemoresistant
ovarian cancer cells became chemosensitive when miR-
200c was ectopically expressed [22]. In another study, Pri-
slei et al. found that high level of miR-200c inhibited the
expression of TUBB3 and was associated with a better
prognosis in ovarian cancer [23]. Moreover, miRNA-182,
miR-376c, and miR-141 have been shown to promote
ovarian cancer growth, metastasis and chemoresistance by
regulating signaling pathways function in these processes
[24-26]. Interestingly, studies have shown that miRNA-
152 and miRNA-185 can function synergistically to in-
crease the chemosensitivity of ovarian cancer cells to the
platinum-based chemotherapy [27].
miR-1307 is located at the intron region of USMG5 gene
in chromosome 10. Has-miR-1307-3p is originated from
the 3’ end of pre-miR-1307 while has-miR-1307-5p comes
from the 5’ end of pre-miR-1307. The function of miR-
1307 is still largely unknown. Zhu et al. reported that 3
miRNAs (hsa-miR-1301, hsa-miR-1307, and hsa-miR-
2110) that were specific to the Epstein-Barr virus-induced
oropharyngeal cancer [28]. However, the role of miR-1307
in the pathogenesis of Epstein-Barr virus-induced oropha-
ryngeal cancer has not been studied. Morin et al. exam-
ined small molecular RNA in embryonic stem cells and
embryoid body by massive parallel signature sequencing
[29]. They discovered that the level of miR-1307 was sig-
nificantly higher in embryonic stem cells than the more
differentiated embryoid body, suggesting that miR-1307
plays a role in the regulation of embryonic stem cell self-
maintenance and differentiation. Although the functional
studies of miR-1307 are still very limited, current evi-
dences support that miR-1307 is associated with cell pro-
liferation, differentiation, and possibly tumorigenesis.
Consistently, our results indicated that miR-1307 was up-
regulated in chemoresistant ovarian cancer cell lines and
tumor tissues, implying an association between miR-1307
and chemoresistance in ovarian cancer. However, the
exact role of miR-1307 in the development of chemoresis-
tance need to be elucidated in future studies.
In the clinicopathological analysis of miR-1307 and
epithelial ovarian cancer, we did not find significant as-
sociations between the expression level of miR-1307 and
the menopause, tumor differentiation status, clinical
stages and lymph node involvement, suggesting that
miR-1307 may not play a role in the ovarian cancer
growth and progression but specific to the development
of chemoresistance. Hence, miR-1307 may be used as a
biomarker of chemosensitivity for ovarian cancer pa-
tients received the platinum-based chemotherapy.
In the bioinformatics analysis, we identified 124 poten-
tial candidate targets of miR-1307, which were enriched
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tumorigenesis, such as the nucleotide synthesis and me-
tabolism, cell proliferation and metabolism. Since the role
of miR-1307 in the development of chemoresistance is still
largely unknown, the study of regulatory targets of miR-
1307 may shed light on the function of miR-1307.
In this study, we successfully validated DAPK3 as a target
of miRNA-1307 using the reporter assay. DAPK3 has been
consistently identified in our analysis for the potential tar-
get of miRNA-1307. Our analysis showed that the 3’-UTR
of DAPK3 contains potential miRNA-1307 binding sites.
DAPK, is also called zipper-interacting protein kinase or
DAPK-like kinase, is located on 19q13.3. The product of
DAPK is a nuclear protein with serine/threonine kinase ac-
tivity. The C-terminal of DAPK3 contains a leucine zipper
motif. The N-terminal of DAPK3 includes a pro-apoptotic
protein kinase domain, which is a shared by all members
of the DAPK family. DAPK3 has been show to function in
apoptosis, autophagy, actin filament regulation, cell migra-
tion, smooth muscle contraction, mitosis, and development
of several types of cancer [30,31]. Since DAPK3 induced
cell apoptosis is mediated by its intrinsic kinase activity,
mutations in the kinase domain of DAPK3 could promote
cell survival, proliferation, and development of chemoresis-
tance [32]. Previous studies have shown that DAPK3 is
widely expressed in many tissues and having the highest
expression level in female reproductive system such as
uterus, ovary, and placenta [33]. The frequency of DAPK3
kinase domain mutations in lung, ovary, and colorectal
cancer is 3.2% compared to the frequency of 1.4% in all
types of cancer, while no DAPK3 mutations have been ob-
served in the corresponding normal tissues [34]. Past stud-
ies have shown that the mutations in DAPK3 kinase
domain increased the anti-apoptotic and survival abilities
of tumor cells and thus reduced the chemosensitivity of
tumor cells [35,36]. However, DAPK3 mutations have not
been detected in all cancer samples. The expression level
of DAPK3 have been shown to regulate the survival and
apoptosis in tumor cells. Overexpression of DAPK3 in-
duced changes in tumor cell morphology, suppressed cell
aggregation, and promoted cell apoptosis [32,37]. There-
fore, the expression level of DAPK3 could be a marker for
cancer migration, invasion, and survival. Overall, the muta-
tions and altered expression of DAPK3 are associated with
the proliferation of cancer cells and the development of
chemoresistance. It will be very interesting to know if
DAPK3 has a role in the miRNA-1307 associated chemore-
sistance in ovarian cancer.
The development of chemoresistance is a complex
process that involved the regulation of multiple factors,
including miRNA. In this study, we discovered that miR-
1307 was upregulated in chemoresistant ovarian cancer
cell lines and tumor tissues compared to the chemosen-
sitive counterparts, supports that miR-1307 is associatedwith the development of chemoresistance in ovarian
cancer. Because the functional study of miR-1307 is still
very limited and the bioinformatics analysis are mostly
based on theoretical prediction, how miR-1307 contrib-
utes to the chemoresistance in ovarian cancer through
the regulation of target genes is still unclear. Therefore,
future study is needed to clarify the function of miR-
1307 in chemoresistance and to provide theoretical
basis for the development of new therapeutics to target
miR-1307. Our results demonstrated that miRNA-1307
is upregulated in chemoresistant ovarian cancer tissues
compared to the chemosensitive counterparts, providing
novel evidences to support that miR-1307 may have a role
in the development of chemoresistance in ovarian cancer
cells.
Additional file
Additional file 1: GO analysis of miR-1307 candidate target genes.
Biological pathway analysis showed that miR-1307 candidate genes were
enriched in organogenesis, gene transcription, cell proliferation and
differentiation, neurogenesis, T cell activation, vitamin synthesis and
metabolism pathways.
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